Cidara Therapeutics IncNASDAQ:CDTX
- LAST PRICE13.4500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots5.3800/ 2
- Ask / Lots13.4900/ 1
- Open / Previous Close--- / 13.4500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CDTX |
|---|---|---|
| 09:39 ET | 100 | 13.584 |
| 09:50 ET | 300 | 13.58 |
| 09:51 ET | 2433 | 13.45 |
| 09:53 ET | 800 | 13.56 |
| 09:57 ET | 998 | 13.57 |
| 10:06 ET | 400 | 13.5974 |
| 10:08 ET | 1998 | 13.6102 |
| 10:09 ET | 263 | 13.63 |
| 11:00 ET | 100 | 13.425 |
| 11:34 ET | 1003 | 13.22 |
| 11:38 ET | 400 | 13.37 |
| 12:30 ET | 847 | 13.3 |
| 12:32 ET | 100 | 13.27 |
| 12:55 ET | 4551 | 13.52 |
| 01:20 ET | 200 | 13.22 |
| 01:22 ET | 151 | 13.35 |
| 01:56 ET | 100 | 13.31 |
| 02:48 ET | 463 | 13.3 |
| 03:37 ET | 133 | 13.3964 |
| 04:00 ET | 631 | 13.45 |
Nov 11, 2024
DJ Cidara Therapeutics Price Target Maintained With a $24.00/Share by HC Wainwright & Co., from 7:56AM ET on Monday Nov 11, 2024 by Dow Jones
7:56AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 8, 2024
DJ Cidara Therapeutics Initiated at Buy by Guggenheim, from 6:41AM ET on Friday Nov 08, 2024 by Dow Jones
6:41AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results, from 4:15PM ET on Thursday Nov 07, 2024 by Dow Jones
4:15PM ET on Thursday Nov 07, 2024 by Dow Jones*DJ Cidara Therapeutics 3Q Loss $16M >CDTX, from 4:15PM ET on Thursday Nov 07, 2024 by Dow Jones
4:15PM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 31, 2024
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cidara Therapeutics Inc | 94.8M | -0.5x | --- |
Protalix Biotherapeutics Inc | 97.1M | -6.5x | --- |
MDxHealth SA | 94.5M | -1.2x | --- |
Bioqual Inc | 60.4M | 126.2x | -25.28% |
MEI Pharma Inc | 20.9M | 1.2x | --- |
Innate Pharma SA | 145.3M | -4.2x | --- |
Company Information
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.
Contact Information
- Headquarters
- 6310 Nancy Ridge Dr Ste 101SAN DIEGO, CA, United States 92121-3209
- Phone
- 858-752-6170
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Daniel Burgess
- President, Chief Executive Officer, Director
- Jeffrey Stein
- Chief Financial Officer
- Preetam Shah
- Chief Operating Officer, Company Secretary
- Shane Ward
- Chief Scientific Officer
- Leslie Tari
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $94.8M |
|---|---|
Revenue (TTM) | $18.9M |
Shares Outstanding | 7.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.98 |
EPS | $-26.06 |
Book Value | $-1.81 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 5.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -678.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
